Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Alloantigenspecific Bcells

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT03916822UnknownPrimary

Cell-based Assays for Antibody-mediated Transplant Rejection

NCT03393793Completed

HEart trAnsplantation Registry of piTie-Salpetriere University Hospital

Showing all 2 trials

Research Network

Common Treatments

  • Alloantigenspecific Bcells1

Active Sponsors

  • Plexision1
  • Lee S Nguyen1
  • Medical University of South Carolina1

Top Investigators

Related Conditions

  • Cardiac Allograft Vasculopathy1
  • Cardiac Transplant Disorder1
  • Immune Tolerance1
  • Cardiac Death1
  • Heart Failure1

Activity Timeline